. 2015 Aug 28;7(2):161–166. doi: 10.1111/1759-7714.12304

Table 3.

Univariate analysis of PFS in chemotherapy and TKI treatment groups

Variable		Cytotoxic chemotherapy group				TKI treatment group
Variable		n	HR	95% CI	P value	n	HR	95% CI	P value
Age at diagnosis	≤65	97	0.721	0.530–1.008	0.056	38	0.871	0.523–1.449	0.595
Age at diagnosis	≥65	68	0.721	0.530–1.008	0.056	47	0.871	0.523–1.449	0.595
Gender	M	73	0.863	0.631–1.181	0.358	26	0.681	0.402–1.153	0.152
Gender	F	92	0.863	0.631–1.181	0.358	59	0.681	0.402–1.153	0.152
Pathology	Adenocarcinoma	150	1.096	0.640–1.875	0.738	79	1.317	0.521–3.331	0.560
Pathology	SqCC or NSCLC not‐subtyped	15	1.096	0.640–1.875	0.738	6	1.317	0.521–3.331	0.560
ECOG PS	0, 1	155	2.573	1.347–4.917	0.004	59	1.469	0.835–2.584	0.182
ECOG PS	≥2	10	2.573	1.347–4.917	0.004	26	1.469	0.835–2.584	0.182
Smoking	Smoker	53	0.989	0.708–1.384	0.950	21	0.737	0.424–1.282	0.280
Smoking	Never‐smoker	112	0.989	0.708–1.384	0.950	64	0.737	0.424–1.282	0.280
Initial disease presentation	Metastatic	129	0.724	0.498–1.051	0.089	65	0.581	0.322–1.049	0.072
Initial disease presentation	Recurred	36	0.724	0.498–1.051	0.089	20	0.581	0.322–1.049	0.072
NLR	≤3	107	2.037	1.454–2.854	0.001	58	1.363	0.777–2.393	0.280
NLR	>3	58	2.037	1.454–2.854	0.001	27	1.363	0.777–2.393	0.280
Initial no. of metastatic sites	1,2	88	1.457	1.059–2.003	0.021	60	2.406	1.389–4.166	0.002
Initial no. of metastatic sites	≥3	77	1.457	1.059–2.003	0.021	25	2.406	1.389–4.166	0.002

CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; NLR, neutrophil‐lymphocyte ratio; NSCLC, non‐small cell lung cancer; PS, performance status; SqCC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor.